DK3164385T3 - Ny polymorf form af n-[2-(6-fluor-lh-indol-3-yl)ethyl]-3-(2,2,3,3-tetrafluorpropoxy)benzylaminhydrochlorid for behandlingen af alzheimers - Google Patents

Ny polymorf form af n-[2-(6-fluor-lh-indol-3-yl)ethyl]-3-(2,2,3,3-tetrafluorpropoxy)benzylaminhydrochlorid for behandlingen af alzheimers Download PDF

Info

Publication number
DK3164385T3
DK3164385T3 DK15733469.9T DK15733469T DK3164385T3 DK 3164385 T3 DK3164385 T3 DK 3164385T3 DK 15733469 T DK15733469 T DK 15733469T DK 3164385 T3 DK3164385 T3 DK 3164385T3
Authority
DK
Denmark
Prior art keywords
tetrafluorpropoxy
alzheimers
indol
fluoro
ethyl
Prior art date
Application number
DK15733469.9T
Other languages
English (en)
Inventor
Kristine Birklund Andersen
Michael Harold Rock
Diego Heidi Lopez De
Frans Dennis Therkelsen
Original Assignee
H Lundbeck As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=58794010&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3164385(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by H Lundbeck As filed Critical H Lundbeck As
Application granted granted Critical
Publication of DK3164385T3 publication Critical patent/DK3164385T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C07D209/16—Tryptamines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DK15733469.9T 2014-07-04 2015-07-03 Ny polymorf form af n-[2-(6-fluor-lh-indol-3-yl)ethyl]-3-(2,2,3,3-tetrafluorpropoxy)benzylaminhydrochlorid for behandlingen af alzheimers DK3164385T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA201400369 2014-07-04
PCT/EP2015/065176 WO2016001398A1 (en) 2014-07-04 2015-07-03 Novel polymorphic form of n-[2-(6-fluoro-lh-indol-3-yl)ethyl]-3-(2,2,3,3-tetrafluoropropoxy)benzylamine hydrochloride for the treatment of alzheimer's

Publications (1)

Publication Number Publication Date
DK3164385T3 true DK3164385T3 (da) 2021-10-11

Family

ID=58794010

Family Applications (1)

Application Number Title Priority Date Filing Date
DK15733469.9T DK3164385T3 (da) 2014-07-04 2015-07-03 Ny polymorf form af n-[2-(6-fluor-lh-indol-3-yl)ethyl]-3-(2,2,3,3-tetrafluorpropoxy)benzylaminhydrochlorid for behandlingen af alzheimers

Country Status (42)

Country Link
US (1) US10071963B2 (da)
EP (1) EP3164385B1 (da)
JP (2) JP6643330B2 (da)
KR (1) KR102399374B1 (da)
CN (3) CN112961094A (da)
AP (1) AP2016009643A0 (da)
AR (1) AR101109A1 (da)
AU (1) AU2015282909B2 (da)
CA (1) CA2951794C (da)
CL (1) CL2017000002A1 (da)
CO (1) CO2017000019A2 (da)
CR (1) CR20160605A (da)
CY (1) CY1124594T1 (da)
DK (1) DK3164385T3 (da)
DO (1) DOP2017000001A (da)
EA (1) EA035894B1 (da)
EC (1) ECSP17000222A (da)
ES (1) ES2893619T3 (da)
GE (2) GEAP202114363A (da)
HR (1) HRP20211596T8 (da)
HU (1) HUE056368T2 (da)
IL (1) IL249428B (da)
JO (1) JO3639B1 (da)
LT (1) LT3164385T (da)
MA (1) MA40345B1 (da)
MX (1) MX377013B (da)
MY (1) MY190715A (da)
NZ (1) NZ727251A (da)
PE (1) PE20170522A1 (da)
PH (1) PH12016502477A1 (da)
PL (1) PL3164385T3 (da)
PT (1) PT3164385T (da)
RS (1) RS62380B1 (da)
RU (1) RU2016151637A (da)
SG (1) SG11201610334XA (da)
SI (1) SI3164385T1 (da)
SM (1) SMT202100575T1 (da)
SV (1) SV2016005353A (da)
TN (1) TN2016000549A1 (da)
TW (1) TWI665188B (da)
UA (1) UA121547C2 (da)
WO (1) WO2016001398A1 (da)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3333154A1 (en) 2016-12-07 2018-06-13 Sandoz Ag Crystalline form of a selective 5-ht6 receptor antagonist

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1859798T3 (da) 2001-03-29 2016-03-21 Lilly Co Eli N-(2-arylethyl) -benzylaminer som antagonister af 5-ht6-receptoren
TW201139370A (en) * 2009-12-23 2011-11-16 Lundbeck & Co As H Processes for the manufacture of a pharmaceutically active agent
JO3459B1 (ar) * 2012-09-09 2020-07-05 H Lundbeck As تركيبات صيدلانية لعلاج مرض الزهايمر
CN105175307A (zh) 2014-11-18 2015-12-23 苏州晶云药物科技有限公司 Lu AE58054的盐酸盐晶型A及其制备方法和用途

Also Published As

Publication number Publication date
PE20170522A1 (es) 2017-05-28
EA035894B1 (ru) 2020-08-27
CO2017000019A2 (es) 2017-05-31
EP3164385A1 (en) 2017-05-10
HUE056368T2 (hu) 2022-02-28
GEP20227368B (en) 2022-03-25
BR112017000127A2 (pt) 2018-01-23
AP2016009643A0 (en) 2016-12-31
RU2016151637A (ru) 2018-08-08
GEAP202114363A (en) 2021-12-10
TW201625525A (zh) 2016-07-16
MA40345B1 (fr) 2021-10-29
IL249428B (en) 2019-10-31
MX2016016895A (es) 2017-04-27
CN112961094A (zh) 2021-06-15
US20170152227A1 (en) 2017-06-01
CL2017000002A1 (es) 2017-06-23
NZ727251A (en) 2023-06-30
UA121547C2 (uk) 2020-06-25
EA201692485A1 (ru) 2017-05-31
HRP20211596T1 (hr) 2022-01-07
AU2015282909A1 (en) 2017-01-05
CR20160605A (es) 2017-04-24
MA40345A (fr) 2021-04-28
KR20170023019A (ko) 2017-03-02
PT3164385T (pt) 2021-10-07
PH12016502477B1 (en) 2017-04-10
MY190715A (en) 2022-05-12
JP2017519829A (ja) 2017-07-20
JP2020059724A (ja) 2020-04-16
US10071963B2 (en) 2018-09-11
KR102399374B1 (ko) 2022-05-17
AR101109A1 (es) 2016-11-23
ECSP17000222A (es) 2017-02-24
ES2893619T3 (es) 2022-02-09
PH12016502477A1 (en) 2017-04-10
CA2951794A1 (en) 2016-01-07
CN112961095A (zh) 2021-06-15
SV2016005353A (es) 2017-03-23
DOP2017000001A (es) 2017-03-31
CY1124594T1 (el) 2022-07-22
JP6643330B2 (ja) 2020-02-12
HRP20211596T8 (hr) 2022-03-04
EP3164385B1 (en) 2021-09-08
CN106458889A (zh) 2017-02-22
SG11201610334XA (en) 2017-01-27
AU2015282909B2 (en) 2019-02-07
CA2951794C (en) 2023-03-07
RU2016151637A3 (da) 2019-01-28
PL3164385T3 (pl) 2021-12-20
SMT202100575T1 (it) 2021-11-12
RS62380B1 (sr) 2021-10-29
MX377013B (es) 2025-03-07
TN2016000549A1 (en) 2018-04-04
TWI665188B (zh) 2019-07-11
SI3164385T1 (sl) 2021-10-29
JO3639B1 (ar) 2020-08-27
IL249428A0 (en) 2017-02-28
WO2016001398A1 (en) 2016-01-07
LT3164385T (lt) 2021-10-11

Similar Documents

Publication Publication Date Title
IL285114B1 (en) Aryl, heteroaryl, and heterocyclic compounds for treatment of complement mediated disorders
PL3681872T3 (pl) Podstawione heteroarylem beta-hydroksyetylaminy do stosowania w leczeniu hiperglikemii
SI3097098T1 (sl) Postopek za pripravo N-((3-aminooksetana-3-il)metil)-2-(1,1-diokso- 3,5-dihidro-1,4-benzotiazepin-4-il)-6-metil-kinazolin-4-amina
HUE058737T2 (hu) Eljárások arenaviridae vírusok okozta fertõzések kezelésére
EP3302575A4 (en) GEMONEDITIERUNGSVEKTOREN
DK3134386T3 (da) Isoindolin-1-on-derivater med kolinerg muscarin-m1-receptor-positiv allosterisk modulatoraktivitet til behandling af alzheimers sygdom
DK3154950T3 (da) N-(cyanmethyl)-4-(2-(4-morpholinphenylamino)pyrimidin-4-yl)benzamidhydrochloridsalte
HUE063043T2 (hu) Eljárás N-(5-(4-(4-formil-3-fenil-1H-pirazol-1-il)-pirimidin-2-il-amino)-4-metoxi-2-morfolinofenil)-akrilamid elõállítására
DK3432912T3 (da) Hsv-vektorer med høj transduktion
HUE045226T2 (hu) Herbicid hatású N-(1,3,4-oxadiazol-2-il)arilkarboxamid-származékok
DK3463351T3 (da) Behandling til parkinsons sygdom
EP3337485A4 (en) CRYSTALLINE FORMS OF IBRUTINIB
DK3373931T3 (da) Heterocykliske forbindelser til behandling af sygdom
LT3506900T (lt) Ampreloksetinas, skirtas naudoti neurogeninės ortostatinės hipotenzijos gydymui
PL3285755T3 (pl) Chlorowodorek kreatyny do leczenia choroby Huntingtona
DK3288949T3 (da) Tetrahydrofuran-fusionerede aminohydrothiazin-derivater, som er anvendelige inden for behandling af Alzheimers sygdom
DK3164385T3 (da) Ny polymorf form af n-[2-(6-fluor-lh-indol-3-yl)ethyl]-3-(2,2,3,3-tetrafluorpropoxy)benzylaminhydrochlorid for behandlingen af alzheimers
LT3290436T (lt) Fenilalanino neturintis baltymas, skirtas fenilketonurijos gydymui
EP3529243C0 (en) (Z)-3-(2-(5-BROMO-1H-INDOLE-3-YL)-2-CYANOVINYL)-4-METHOXYBENZONITRILE FOR THE TREATMENT OF ENDOMETRIOSIS
IT201700035964A1 (it) “divisorio per boiserie”
PL3153022T3 (pl) N-(3’,4’-dichloro-5-metoksybifenyl-2-ylo)-3-(difluorometylo)-1-metylo-1H-pirazolo-4-karboksyamid
ITUB20153121A1 (it) Apparato per l'ozonoterapia
ZA201603729B (en) Process for the preparation of n-[(3-aminooxetan-3-yl)methyl]-2-(1,1-dioxo-3,5-dihydro-1,4-benzothiazepin-4-yl)-6-methyl-quinazolin-4-amine
IT201600112690A1 (it) Macchina per il trattamento di superfici pavimentate.
DK3119747T3 (da) Fremgangsmåde til fremstilling af n-[(6-chlorpyridin-3-yl)methyl]-2,2-difluorethan-1-amin ved hjælp af alkylering af 2,2-difluorethylamin